Abstract
SUMMARY: Natalizumab is a humanized IgG4κ monoclonal antibody that is a selective adhesion molecule inhibitor, which prevents adhesion of leukocytes to endothelial cells. It is the first monoclonal antibody approved by the FDA for the treatment of relapsing-remitting MS. This article will review the mechanism of action and clinical role of this agent.
Abbreviations
- FDA
- US Food and Drug Administration
- FLAIR
- fluid-attenuated inversion recovery
- FSE
- fast spin-echo
- IgG
- immunoglobulin G
- MAdCAM-1
- mucosal adressin cell adhesion molecule
- MS
- multiple sclerosis
- PML
- progressive multifocal leukoencephalopathy
- TOUCH
- Tysabri Outreach Unified Commitment to Health
- VCAM -1
- vascular cell adhesion molecule-1
- Copyright © American Society of Neuroradiology
